Although we intervened with anti-IL-17A antibodies at different HIRI stages in an attempt to counteract the pro-inflammatory effects of IL-17A, interventions at the end of ischemia and 1 h of reperfusion were not as effective as earlier (pre-ischemic) strategies. This evidence concerns the gene IL17A and ischemia.